by Raynovich Rod | Mar 28, 2012 | BIOgraph, Biopharmaceuticals, Clinical Diagnostics and Tools
Two Companies With Major Biotech Themes: Orphan Drugs (ALXN) and Targeted Cancer Therapy (RGDX) IBB ($122) Weak Down 1% – 52 Week High of $124 One of our Top Performers in the biopharmaceutical sector Alexion (ALXN $89) took a hit this week and down over 3%...
by Raynovich Rod | Mar 21, 2012 | 2024 Rayno Tools and Diagnostics Portfolio, BIOgraph, Biopharmaceuticals
Diagnostics Stocks Are Relatively Calm After Patent News: But Patents Still Matter The Supreme Court Ruling threw out two process patents on diagnostic tests because they were based on the laws of nature and that they were merely telling doctors of a new scientific...
by Raynovich Rod | Mar 13, 2012 | BIOgraph, Biopharmaceuticals, Clinical Diagnostics and Tools
Biotech Sector (IBB $119.73) Up 12 % YTD, Lagging NASDAQ (QQQ) Up 17.85% Here is a summary of our recommendations over the past month: No change in our basic Rayno Life Science Portfolios.Biopharmaceuticals have outperformed Tools and Diagnostics. Continued strength...
by Raynovich Rod | Mar 8, 2012 | BIOgraph, Biopharmaceuticals
Biotech Sector Recovers from Monday’s Weakness-Bull Intact Biotech stocks are strong today tracking a NASDAQ rally and favorable news on JNJ’s prostate drug Zytiga which met its goal in a new study. Dendreon stock took a big hit down 10% because the JNJ...
by Raynovich Rod | Mar 6, 2012 | BIOgraph, Biopharmaceuticals
Smaller Cap Biotechs In Major Correction All the major indices are down in the 1.75% range and now the NASDAQ at 2902 is 100 pts. away from the elusive 3000 level. Analysts have been warning about a correction for weeks but with many indices up 10-15% YTD profit...
by Raynovich Rod | Feb 28, 2012 | BIOgraph, Biopharmaceuticals, Clinical Diagnostics and Tools
Not A Good Time To Overweight Biotech Positions We are still in a holding pattern and recommend that caution be exercised regarding new positions. Although biotech stocks have made a nice run over the past five days driven by News from Vivus (VVUS) and Threshold...
by Raynovich Rod | Feb 17, 2012 | BIOgraph, Biopharmaceuticals
$11B bet on Pharmasset acquisition for Hepatitus -C drug hits a snag Gilead announced that a majority (6/8) of the hepatitis C genotype-1 patients experienced a viral relapse when treated with GS-7977 Plus Ribavirin. Additional data will be forthcoming by the end of...
by Raynovich Rod | Feb 13, 2012 | BIOgraph, Biopharmaceuticals, Clinical Diagnostics and Tools
Who Does Not Know About the Bull Market in Biotech Stocks? The bull market in life science stocks gathered momentum today as the IBB rallied 2.34% (up 16.6% YTD) approaching its all time high of $122.45. At some point in time we need to have a correction as this rally...
by Raynovich Rod | Feb 2, 2012 | BIOgraph, Clinical Diagnostics and Tools
Early Player in Genetic Testing and Personalized Medicine Reloads RGDX Stock Trades Up 36% on Volume of 105k Shares at $1.60 Response Genetics (RGDX) announced today that it has entered purchase agreements with private investors including current holders to raise...
by Raynovich Rod | Feb 1, 2012 | BIOgraph, Biopharmaceuticals
The IBB hit another new high today at $118.85 as the biotech bull market rolls on. Our index of biopharmaceutical stocks were up 4% at one time propelled by Medivation (MDVN $67.67) up 22% on favorable clinical news on its prostate cancer drug. A WSJ story helped move...
